For drug discovery teams advancing complex peptides, small molecules and new modalities, IRBM's expanded Purification and Automation Suite delivers a faster, more reliable path from…
The decision to advance a candidate is only as sound as the data behind it. Every PK/PD profile, every efficacy readout, every biomarker result carries…
Rome, Italy — February 10, 2026 — IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of…
We’ve recently expanded our mass spectrometry and imaging capabilities with the installation of Bruker’s rapifleX® MALDI Tissuetyper®, making IRBM the first CRO in Italy to adopt…
Prestigious bilingual publication highlights 30 standout companies shaping the future of Italian enterprise—from design and fashion to science and technology Rome, Italy – April 15,…
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /originally distributed by PRNewswire/– IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery,…
Covalent inhibitors have become a key strategy in drug discovery, offering advantages such as prolonged target engagement, high potency, and selectivity. However, identifying high-quality covalent…
At IRBM, we believe that scientific excellence thrives in environments where diverse perspectives are not only welcomed but embedded at every level of an organization…
On October 24, 2024, IRBM's CEO Matteo Liguori represented the organization at the G7 Ministerial Meeting on Development. This high-level event gathered Development Ministers from…
The IRBM Group Achieves EcoVadis Gold Rating: Leading the Way in Sustainability in the Life Sciences Sector At the IRBM Group, we believe that every…
Dublin, Ireland, and Rome, Italy, 20 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug…
This year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego showcased a series of high-impact presentations, with IRBM spotlighting novel therapeutic agents…
